Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluating Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE) (BESAFE)

18 november 2026 bijgewerkt door: IRCCS Policlinico S. Donato

An Open Label, Single Arm, Explorative Trial to Evaluate Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE)

The primary aim of the study is to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with Acquired Angioedema (AAE-C1-INH).

Studie Overzicht

Toestand

Nog niet aan het werven

Interventie / Behandeling

Gedetailleerde beschrijving

This study aims to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with AAE-C1-INH and to evaluate its safety profile. This is an open label single arm study. Each eligible subject who consents to participate in the study will receive 24 weeks (168 days) of oral Berotralstat (150 mg). All subjects will undergo a screening period (including a prospective AAE-C1-INH attack run- in period between 28 and 56 days) and will then enter the treatment phase. During this phase, there will be follow-up assessments (at 29, 85 and 169 days) including physical examination, vital signs assessment, blood and urine analysis, 12-lead ECG and PROMs evaluation. Details on AAE-C1-INH attacks, concomitant medications and adverse events will be collected through the course of the study.

Studietype

Ingrijpend

Inschrijving (Geschat)

16

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Palermo, Italië, 90146
        • A.O. "Ospedali Riuniti Villa Sofia-Cervello"
        • Contact:
    • Milan
      • Milan, Milan, Italië, 20157
      • San Donato Milanese, Milan, Italië, 20097
        • IRCCS Policlinico San Donato
        • Contact:
    • Naples
      • Naples, Naples, Italië, 80131
        • Università degli Studi di Napoli Federico II
        • Contact:
          • Giuseppe Spadaro, MD
          • Telefoonnummer: (+39) 0817462279
          • E-mail: spadaro@unina.it
    • Padua
      • Padova, Padua, Italië, 35128
        • Azienda Ospedale-Università di Padova
        • Contact:
    • Rome
      • Roma, Rome, Italië, 00133
    • Turin
      • Torino, Turin, Italië, 10128
        • AO Ordine Mauriziano di Torino
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Males and non-pregnant, non-lactating females ≥ 18 years of age

  2. Able to provide written, informed consent.

  3. Subject weight of ≥ 40 kg

  4. A clinical diagnosis of AAE is defined from the following criteria:

    • Recurrent angioedema without wheals

    • No family history of angioedema and/or C1-INH deficiency

    • C1-inhibitor activity level of <50% of normal and at least 1 of the following:

      • Age at least 40 years at reported onset of first angioedema symptoms
      • Reduced C1q level (below the lower limit of normal), recognizing that normal C1q levels do not exclude the diagnosis of AAE. Absence of a pathogenic variant in the SERPING1 gene encoding for the C1-inhibitor protein.
      • Serologic confirmation of anti-C1-inhibitor antibodies.
  5. Access to and ability to use one or more acute medications approved by the relevant competent authority for the treatment of acute attacks of HAE (icatibant, plasmaderived C1-INH).

  6. The subject must have at least 2 AAE attacks which meet all the requirements below during the run-in period of 28 days. In case of not recurrence of 2 attacks in 28 days or attacks do not meet all the requirements below, the run-in period will be extended to a maximum of 56 days from the Screening visit:

    • The attacks are unique, which is defined as an attack that does not begin within 48 hours of the end of a previous attack.
    • The attacks must include symptoms of swelling. Symptoms of swelling, in addition to visible swelling, may also include symptoms in the oropharyngeal or abdominal regions which are indicative of internal swelling.
    • The attacks are confirmed by the Investigator to be AAE attacks. Subjects will be contacted within 2 business days of the attack to discuss the attack, any queries on the entered data in the diary, as applicable.
  7. In the opinion of the Investigator, the subject is expected to adequately comply with all required study procedures for the duration of the study. The subject must demonstrate adequate compliance with all study procedures required from the screening visit, including diary recording of HAE attacks beginning at the screening visit. Women of childbearing potential and male participants with partners of childbearing potential must agree to use a highly effective method of contraception, throughout the study and for the protocol-defined period after the last dose of the investigational medicinal product (IMP). Acceptable highly effective methods include combined (estrogen- and progestogen-containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine devices (IUDs), intrauterine hormone-releasing systems (IUSs), bilateral tubal occlusion, vasectomized partner (provided he is the sole sexual partner), and true sexual abstinence when this is the participant's usual and preferred lifesty.

Exclusion Criteria:

  1. Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study or increases the risk to the subject by participating in the study

  2. Concurrent diagnosis of any other type of recurrent angioedema

  3. Any abnormal clinical, laboratory or urinalysis parameter at screening that, in the opinion of the Investigator or any contraindication describe in berotralstat SmPC

  4. Known hypersensitivity to the active substance of berotralstat or to any of its excipients

  5. Current treatment with any long-term prophylactic therapy intended for the prevention of angioedema attacks, unless the required washout period has been completed before the start of the run-in period. Required washout periods are as follows:

    • plasma-derived or recombinant C1 inhibitor used for long-term prophylaxis: 14 days;
    • lanadelumab: 28 days;
    • berotralstat or any other oral plasma kallikrein inhibitor: 28 days;
    • attenuated androgens (e.g., danazol): 28 days;
    • tranexamic acid: 28 days;
    • any other investigational or approved long-term prophylactic treatment for angioedema: at least 28 days, or 5 half-lives, whichever is longer.

    Use of approved on-demand (rescue) therapies for the treatment of acute angioedema attacks (e.g., icatibant or plasma-derived C1 inhibitor) is permitted throughout the study, including during the run-in period and the treatment period, according to standard clinical practice.

  6. Pregnant women

  7. Patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) in alignment with SmPC requirement

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Berotralstat Treatment

Patients will receive capsules of oral Berotralstat for 24 weeks until the end of the study.

Patients will receive capsules of oral Berotralstat for 24 weeks until the end of the study.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Berotralstat Effectiveness
Tijdsspanne: Up to 24 weeks.

The primary objective of the study is to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with AAE-C1-INH. The primary efficacy endpoint is the change in the monthly HAE attacks rate, from week 1 to week 24 of treatment compared to attack rate during the run-in period.

Up to 24 weeks.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Berotralstat Safety
Tijdsspanne: Up to 24 weeks.

The safety objective is to evaluate the proportion of patients with adverse events (AEs) including treatment-emergent serious adverse events (TESAEs).

Up to 24 weeks.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Andrea Zanichelli, PhD, MD, IRCCS Policlinico S. Donato

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

15 november 2026

Primaire voltooiing (Geschat)

31 december 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

19 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

18 november 2026

Eerst geplaatst (Werkelijk)

20 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 november 2026

Laatste update ingediend die voldeed aan QC-criteria

18 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • BESAFE

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren